Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Marc A Dall’Era, Liang Cheng & Chong-Xian Pan. (2012) Contemporary management of muscle-invasive bladder cancer. Expert Review of Anticancer Therapy 12:7, pages 941-950.
Read now
Read now
Lars Fokdal, Morten Høyer & Hans von der Maase. (2006) Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Review of Anticancer Therapy 6:2, pages 269-279.
Read now
Read now
Articles from other publishers (41)
Raquel Carrasco, Mercedes Ingelmo-Torres, Josep Oriola, Fiorella L. Roldán, Leonardo Rodríguez-Carunchio, Sandra Herranz, Begoña Mellado, Antonio Alcaraz, Laura Izquierdo & Lourdes Mengual. (2023) Assessment of aggressive bladder cancer mutations in plasma cell-free DNA. Frontiers in Oncology 13.
Crossref
Crossref
Gunhild von Amsberg, Margitta Retz, Maria De Santis & Günter Niegisch. (2022) Erstlinientherapie des metastasierten Urothelkarzinoms: ein UpdateFirst-line treatment of metastatic urothelial carcinoma: an update. Die Onkologie 28:9, pages 792-798.
Crossref
Crossref
Ming-Kun Chen, Jun-Hao Zhou, Peng Wang, Yun-lin Ye, Yang Liu, Jia-Wei Zhou, Zi-Jian Chen, Jian-Kun Yang, De-Ying Liao, Zhi-Jian Liang, Xiao Xie, Qi-Zhao Zhou, Kang-Yi Xue, Wen-Bin Guo, Ming Xia, Ji-Ming Bao, Cheng Yang, Hai-Feng Duan, Hong-Yi Wang, Zhi-Peng Huang, Zi-Ke Qin & Cun-Dong Liu. (2021) BMI1 activates P-glycoprotein via transcription repression of miR-3682-3p and enhances chemoresistance of bladder cancer cell. Aging 13:14, pages 18310-18330.
Crossref
Crossref
Jianzheng Wang, Qingli Li, Huifang Lv, Caiyun Nie, Beibei Chen, Weifeng Xu, Tiejun Yang, Yinping Zhang, Shuiping Tu & Xiaobing Chen. (2021) A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report. Frontiers in Oncology 11.
Crossref
Crossref
M. Rouprêt, G. Pignot, A. Masson-Lecomte, E. Compérat, F. Audenet, M. Roumiguié, N. Houédé, S. Larré, S. Brunelle, E. Xylinas, Y. Neuzillet & A. Méjean. (2020) Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : tumeurs de la vessie. Progrès en Urologie 30:12, pages S78-S135.
Crossref
Crossref
Alessandro Tafuri, David D. Smith, Giovanni E. Cacciamani, Sarah Cole, Aliasger Shakir, Sarmad Sadeghi, Nicholas J. Vogelzang, David Quinn, Parkash S. Gill & Inderbir S. Gill. (2020) Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clinical Genitourinary Cancer 18:5, pages 351-360.e3.
Crossref
Crossref
M. Rouprêt, Y. Neuzillet, G. Pignot, E. Compérat, F. Audenet, N. Houédé, S. Larré, A. Masson-Lecomte, P. Colin, S. Brunelle, E. Xylinas, M. Roumiguié & A. Méjean. (2018) Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : tumeurs de la vessie. Progrès en Urologie 28, pages R48-R80.
Crossref
Crossref
M. Rouprêt, Y. Neuzillet, G. Pignot, E. Compérat, F. Audenet, N. Houédé, S. Larré, A. Masson-Lecomte, P. Colin, S. Brunelle, E. Xylinas, M. Roumiguié & A. Méjean. (2018) RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU — Actualisation 2018—2020 : tumeurs de la vessie. Progrès en Urologie 28:12, pages S46-S78.
Crossref
Crossref
N. Houédé, G. Locker, C. Lucas, H. Soto Parra, U. Basso, D. Spaeth, R. Tambaro, L. Basterretxea, F. Morelli, C. Theodore, L. Lusuardi, N. Lainez, A. Guillot, G. Tonini, J. Bielle & X. Garcia Del Muro. (2016) Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC Cancer 16:1.
Crossref
Crossref
Mathilde B.H. Thomsen, Iver Nordentoft, Philippe Lamy, Søren Høyer, Søren Vang, Jakob Hedegaard, Michael Borre, Jørgen B. Jensen, Torben F. Ørntoft & Lars Dyrskjøt. (2016) Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Molecular Oncology 10:9, pages 1450-1460.
Crossref
Crossref
M. Rouprêt, Y. Neuzillet, A. Masson-Lecomte, P. Colin, E. Compérat, F. Dubosq, N. Houédé, S. Larré, G. Pignot, P. Puech, M. Roumiguié, E. Xylinas & A. Méjean. (2016) Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la vessie. Progrès en Urologie 27, pages S67-S91.
Crossref
Crossref
Joaquim Bellmunt, Nicolas Mottet & Maria De Santis. (2016) Urothelial carcinoma management in elderly or unfit patients. European Journal of Cancer Supplements 14:1, pages 1-20.
Crossref
Crossref
Ki Hong Kim, Sung Joon Hong & Kyung Seok Han. (2015) Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP). BMC Cancer 15:1.
Crossref
Crossref
Jung Hyun Lee, Sung Gu Kang, Seung Tae Kim, Seok Ho Kang, In Keun Choi, Young Je Park, Sang Chul Oh, Deuk Jae Sung, Jae Hong Seo, Jun Cheon, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim & Kyong Hwa Park. (2014) Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment. Cancer Research and Treatment 46:2, pages 172-177.
Crossref
Crossref
L. Guy, H. Mahammedi, C. Bastide, F. Bruyere, G. Karsenty & J.-O. Bay. (2013) Les médicaments du cancer de vessie. Progrès en Urologie 23:15, pages 1238-1245.
Crossref
Crossref
C. Pfister, M. Roupret, Y. Neuzillet, S. Larré, G. Pignot, H. Quintens, N. Houedé, E. Compérat, P. Colin, C. Roy, J.-L. Davin, L. Guy, J. Irani, T. Lebret, P. Coloby & M. Soulié. (2013) Recommandations en onco-urologie 2013 du CCAFU : Tumeurs de la vessie. Progrès en Urologie 23, pages S105-S125.
Crossref
Crossref
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, Lai Wei, Mitch A. Phelps, Zhongfa Liu, Erica J. Harper, S. Percy Ivy, Xin Wu, Bing-Sen Zhou, Xiyong Liu, Deidre Deam, J. Paul Monk, William J. Hicks, Yun Yen, Gregory A. Otterson, Michael R. Grever & Tanios Bekaii-Saab. (2012) A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Investigational New Drugs 31:3, pages 685-695.
Crossref
Crossref
Kyriaki Pliarchopoulou, Konstantinos Laschos & Dimitrios Pectasides. (2013) Current chemotherapeutic options for the treatment of advanced bladder cancer: A review. Urologic Oncology: Seminars and Original Investigations 31:3, pages 294-302.
Crossref
Crossref
Maria De SantisJoaquim BellmuntGraham MeadJ. Martijn KerstMichael LeahyPablo MarotoThierry GilSandrine MarreaudGedske DaugaardIwona SkonecznaSandra ColletteJulie LorentRonald de WitRichard Sylvester. (2012) Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology 30:2, pages 191-199.
Crossref
Crossref
Andrea Tubaro, Daniele Santini, Cosimo De Nunzio, Alice Zoccoli & Michele Iuliano. 2012. Biotargets of Cancer in Current Clinical Practice. Biotargets of Cancer in Current Clinical Practice
325
354
.
O. I. Iatsyna, E. O. Stakhovsky, Ya. A. Sheremet, S. I. Spivak, O. E. Stakhovsky, O. N. Gavrilyuk, Yu. V. Vitruk, A. I. Emets, Ya. B. Blyum & S. V. Vernygorodskyi. (2011) Specific features of the apoptotic response of urinary bladder cancer cells to neoadjuvant chemotherapy. Cytology and Genetics 45:4, pages 201-207.
Crossref
Crossref
Yuuki Kyoda, Yasuharu Kunishima & Fumimasa Fukuta. (2011) EXPERIENCE WITH GEMCITABINE MONOTHERAPY IN THREE PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA. The Japanese Journal of Urology 102:5, pages 701-704.
Crossref
Crossref
Maria De Santis & Mark Bachner. 2011. Bladder Tumors:. Bladder Tumors:
409
431
.
C. Pfister, M. Roupret, H. Wallerand, J.-L. Davin, H. Quintens, L. Guy, N. Houede, S. Bernardini, S. Larré, C. Mazerolles, C. Roy, D. Amsellem, F. Saint, J. Irani & M. Soulié. (2010) Recommandations en Onco-Urologie 2010 : Tumeurs urothéliales. Progrès en Urologie 20, pages S255-S274.
Crossref
Crossref
Maria De SantisJoaquim BellmuntGraham MeadJ. Martijn KerstMichael LeahyPablo MarotoIwona SkonecznaSandrine MarreaudRonald de WitRichard Sylvester. (2009) Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986. Journal of Clinical Oncology 27:33, pages 5634-5639.
Crossref
Crossref
Fabio Calabrò, Vito Lorusso, Gerardo Rosati, Luigi Manzione, Luca Frassineti, Teodoro Sava, Eugenio Donato Di Paula, Silvia Alonso & Cora N. Sternberg. (2009) Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 115:12, pages 2652-2659.
Crossref
Crossref
Deborah Bradley & Maha Hussain. 2010. Bladder Cancer. Bladder Cancer
247
262
.
T. Lebret & A. Méjean. (2008) Les métastases des cancers urothéliaux : place de la chimiothérapie. Progrès en Urologie 18, pages S261-S276.
Crossref
Crossref
David J. Gallagher, Matthew I. Milowsky & Dean F. Bajorin. (2008) Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 113:6, pages 1284-1293.
Crossref
Crossref
Hans von der Maase. (2007) Editorial Comment on: Weekly Paclitaxel and Carboplatin against Advanced Transitional Cell Cancer after Failure of a Platinum-Based Regimen. European Urology 52:4, pages 1122.
Crossref
Crossref
Maria De Santis & Mark Bachner. (2007) New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Current Opinion in Urology 17:5, pages 363-368.
Crossref
Crossref
Joaquim Bellmunt & Santiago Albiol. (2007) Chemotherapy for Metastatic or Unresectable Bladder Cancer. Seminars in Oncology 34:2, pages 135-144.
Crossref
Crossref
Cora N. Sternberg, S. Machele Donat, Joaquim Bellmunt, Randall E. Millikan, Walter Stadler, Pieter De Mulder, Amir Sherif, Hans von der Maase, Taiji Tsukamoto & Mark S. Soloway. (2007) Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer. Urology 69:1, pages 62-79.
Crossref
Crossref
H. von der Maase, J. Lehmann, G. Gravis, H. Joensuu, P.F. Geertsen, J. Gough, G. Chen & M. Kania. (2006) A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Annals of Oncology 17:10, pages 1533-1538.
Crossref
Crossref
C.N. Sternberg. (2006) Muscle invasive and metastatic bladder cancer. Annals of Oncology 17, pages x23-x30.
Crossref
Crossref
J.T. Roberts, H. von der Maase, L. Sengeløv, P.F. Conte, L. Dogliotti, T. Oliver, M.J. Moore, A. Zimmermann & M. Arning. (2006) Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Annals of Oncology 17, pages v118-v122.
Crossref
Crossref
J. Bellmunt, S. Albiol, A. Ramírez de Olano, J. Pujadas & P. Maroto. (2006) Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Annals of Oncology 17, pages v113-v117.
Crossref
Crossref
Benjamin SolomonPaul A Bunn Jr. (2005) Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Future Oncology 1:6, pages 733-746.
Crossref
Crossref
Hans von der Maase, Lisa Sengelov, James T. Roberts, Sergio Ricci, Luigi Dogliotti, T. Oliver, Malcolm J. Moore, Annamaria Zimmermann & Michael Arning. (2005) Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. Journal of Clinical Oncology 23:21, pages 4602-4608.
Crossref
Crossref
Dimitrios Pectasides, Melina Pectasides & Maria Nikolaou. (2005) Adjuvant and Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Literature Review. European Urology 48:1, pages 60-68.
Crossref
Crossref
Hans von der Maase & Lisa Sengel??v. (2005) Chemotherapy in Locally Advanced and Metastatic Bladder Cancer. American Journal of Cancer 4:1, pages 1-13.
Crossref
Crossref